On September 8, 2023 PharmaMar (MSE:PHM) reported five abstracts to be presented at the IASLC World Lung Cancer Congress 2023 on its compound Zepzelca (lurbinectedin) (Press release, PharmaMar, SEP 8, 2023, View Source [SID1234635029]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Among the most important studies to be made public are the following: "Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial". Patients with platinum-sensitive, relapsed Small Cell Lung Cancer (SCLC) who received platinum re-challenge immediately after lurbinectedin + doxorubicin showed longer survival compared to those who received it after topotecan/CAV, thereby suggesting that giving lurbinectedin as second line to platinum-sensitive, relapsed SCLC patients does not affect the efficacy of subsequent platinum re-challenge and could extend the platinum-free interval and improve patient survival.
"Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients". These results suggest that lurbinectedin may effectively extend the platinum-free interval while maintaining the possibility of platinum re-challenge, leading to improved outcomes for patients with relapsed SCLC.
As part of the conclusion of the last two posters, Dr Ali Zeaiter, VP and Head of Clinical Development at PharmaMar says: "the effect of platinum re-challenge after lurbinectedin given as monotherapy or in combination with doxorubicin is similar to that previously reported with platinum re-challenge as second line therapy in platinum-sensitive patients (Baize et al., 2020). This supports that lurbinectedin is an alternative second line treatment option to platinum re-challenge for patients with platinum-sensitive relapsed SCLC".
"Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Data Study". The safety and effectiveness outcomes of lurbinectedin in relapsed Small Cell Lung Cancer (SCLC) in the real world were generally consistent with those seen in the phase II trial. In addition, the rates of neutropenia, thrombocytopenia, anemia and febrile neutropenia tended to be lower than what was observed in the basket trial.
"Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis." The study continues to enroll a broader population of SCLC patients than the collective Phase II trial that supported FDA approval. The real-world safety profile of lurbinectedin in this analysis was generally consistent with those reported in the collective trial, with no new safety events. The prophylactic use of G-CSF likely contributed to the low rates of neutropenia reported.
Lurbinectedin’s abstracts at the IASCL 2023 World Lung Cancer Congress
PRODUCT TITLE LEAD AUTHOR ABSTRACT
Zepzelca (lurbinectedin) Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer A.K. Ganti ABSTRACT: P2.17-02 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial Alejandro Navarro ABSTRACT: P2.17-06 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis B. Halmos ABSTRACT: P2.17-07 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients J.M Trigo ABSTRACT: EP13.07-06 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Cost- Effectiveness Modeling of Lurbinectedin As a Second-line Therapy in Patients with Small Cell Lung Cancer Wayne Su